mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity
Shots:
- mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4-000L CSR Bioreactor
- The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site
- The 4-000L volume & performance comparable to stainless steel systems will enable mAbxience to improve flexibility- productivity and efficiency. The CSR bioreactor design also allows for seamless scale-up and transfer of cell culture processes- thereby reducing time to market for mAbxience’s products
Ref: Businesswire | Image: mAbxience
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com